Skip to Main Content
scipher medicine
  • Company
  • Solutions
  • Resources
  • Contact Us
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis

Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis

Dec 30, 2021

Vibeke Strand, Stanley B. Cohen, Jeffrey R. Curtis, Lixia Zhang, Alan J. Kivitz, Robert W. Levin, Angela Mathis, Erin Connolly-Strong, and Johanna B. Withers Expert Review of...
Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility

Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility

Dec 1, 2021

Christopher Arnell, MBA; Martin Bergman, MD; Dhiman Basu, MD; James T Kenney, RPh, MBA; Johanna B Withers, PhD; Jennifer Logan, PhD; Jeraldine Lim Harashima, MS, CGC; and Erin Connolly-Strong, PhD J Manag Care Spec Pharm. 2021;27(12):1734-42 Abstract: Objectives: To...
A molecular signature response classifier to predict inadequate response to tumor necrosis factor-α Inhibitors: the NETWORK-004 Prospective Observational Study

A molecular signature response classifier to predict inadequate response to tumor necrosis factor-α Inhibitors: the NETWORK-004 Prospective Observational Study

Nov 10, 2021

Stanley Cohen, Alvin F. Wells, Jeffrey R. Curtis, Rajat Dhar, Theodore Mellors, Lixia Zhang, Johanna B. Withers, Alex Jones, Susan D. Ghiassian, Mengran Wang, Erin Connolly-Strong, Sarah Rapisardo, Zoran Gatalica, Dimitrios A. Pappas, Joel M. Kremer, Alif Saleh &...
Discontinuation of TNFi treatment among Rheumatoid Arthritis patients with a molecular signature of non-response to tumor necrosis factor-ɑ inhibitor therapies

Discontinuation of TNFi treatment among Rheumatoid Arthritis patients with a molecular signature of non-response to tumor necrosis factor-ɑ inhibitor therapies

Nov 8, 2021

Jeffrey Curtis, Joel Kremer, Dimitrios Pappas, Lixia Zhang, Erin Connolly-Strong, Johanna Withers, Viatcheslav Akmae and Alif Saleh Abstract: Background: A 23-feature blood-based molecular signature response classifier1 (MSRC) identifies rheumatoid arthritis (RA)...
A molecular signature response classifier predicts the likelihood of non-response to TNF inhibitor therapies in RA at 3 months

A molecular signature response classifier predicts the likelihood of non-response to TNF inhibitor therapies in RA at 3 months

Nov 8, 2021

Stanley Cohen, Theodore Mellors, Lixia Zhang, Alex Jones, Erin Connolly-Strong, Dimitrios Pappas, Joel Kremer, Johanna Withers and Viatcheslav Akmae ACR Convergence 2021 Abstract: Background: Most people with rheumatoid arthritis (RA) are prescribed a TNF inhibitor...
Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis

Analytical and clinical validation of an RNA sequencing-based assay for quantitative, accurate evaluation of a molecular signature response classifier in rheumatoid arthritis

Oct 26, 2021

Alex Jones, Sarah Rapisardo, Lixia Zhang, Theodore Mellors, Johanna B. Withers, Zoran Gatalica, and Viatcheslav R. Akmaev Abstract: Objectives: This study reports analytical and clinical validation of a molecular signature response classifier (MSRC) that identifies...
« Older Entries
Next Entries »
Scipher Medicine Logo

Company

  • About Us
  • Team/Advisors
  • Careers

Solutions

  • Diagnostics
  • Data Lake
  • Therapeutics
  • Market Access

Resources

  • News/Events
  • Press
  • Publications
  • Media Kit
Contact Us

info@sciphermedicine.com

Privacy Policy / Patient Opt-out Information / Notice of Privacy Practices / Terms of Use / Cookies Acknowledgement / Notice of Nondiscrimination

© 2024 Scipher Medicine. All rights reserved. Privacy Policy